BYDUREON BCISE
PeakNDASUBCUTANEOUSSUSPENSION, EXTENDED RELEASE
Approved
Oct 2017
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
3/8 — Basic
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BYDUREON BCISE is an extended-release subcutaneous suspension approved in 2017 for type 2 diabetes management. It is a small-molecule GLP-1 receptor agonist delivered via a convenient prefilled pen formulation. The drug works by enhancing insulin secretion and improving glycemic control in patients with inadequate disease management.
$284MPart D
Peak4.8 years to LOEThe product is at peak lifecycle with stable $284M annual spending and over 212K claims, suggesting a mature, well-established brand team with focus on market penetration and competitive defense.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~5 years — strategic planning for patent cliff underway
Worked on BYDUREON BCISE at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.